Praxis Posts $94.2M Q3 Loss, $1.3B Cash Ahead of Two FDA Decisions
PRAX sits 69% above its 52-week low of $159.735.
Summary
Praxis reported a Q3 2026 net loss of $94.2M, wider than the $73.9M loss a year ago, as G&A expense jumped to $42.7M from $12.6M while R&D slipped to $64.2M from $65.8M. The loss per share was $3.23. Cash and investments stood at $1.3B on September 30, 2026, up from $926.1M at December 31, 2025, with the company guiding runway into 2028. The balance sheet removes near-term financing risk, but the widening loss and G&A step-up are the numbers to weigh against the clinical story. Two FDA decisions anchor the thesis: relutrigine has a PDUFA date of December 27, 2026, and ulixacaltamide January 29, 2027. EMERALD topline results are expected in the fourth quarter of 2026.
At the time of this announcement, PRAX was trading at $270.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.8B. The 52-week trading range was $159.74 to $392.70. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Wiseek News.